Digital pathology firm Proscia and artificial intelligence (AI) biotech company Owkin have signed an agreement to make Owkin's colorectal cancer (CRC) diagnostic test available through Proscia's digital pathology software platform.
In a statement, Proscia said that it will integrate Owkin's MSIntuit CRC v2 test into its Proscia Concentriq software platform as part of its precision medicine testing portfolio. Financial and other terms of the agreement were not disclosed.
The MSIntuit CRC v2 is an AI-based screening test developed to identify microsatellite instability and aid in the management of CRC, according to the Paris-based Owkin; the results can help identify patients eligible for treatment with immune checkpoint inhibitors or chemotherapy. It is the updated version of the company's CE-marked MSIntuit CRC test; MSIntuit CRC v2 will also be submitted for CE marking in the European Union and is currently for research use only in the U.S., the companies noted.
As part of the agreement, Owkin has also joined the Proscia Ready interoperability alliance that Proscia launched earlier this year, aimed at ensuring that hardware and software components from firms in the alliance work together as seamlessly as possible, the firms added.
